Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice.
Neurological deficit in experimental allergic encephalomyelitis (EAE) and multiple sclerosis (MS) is probably a consequence of synergy between T and B cell responses to CNS antigens. During the demyelinating phase of chronic relapsing EAE in ABH mice, anti-myelin oligodendrocyte glycoprotein (MOG) responses were increased compared to the inflammatory acute phase, but such levels did not correlate with the severity of clinical disease. The pathogenicity of antibodies (Ab) to MOG, myelin basic protein (MBP), proteolipid protein (PLP) and galactocerebroside (GalC) was investigated in vivo following injection at the onset of EAE. An IgG2a monoclonal Ab (mAb), clone Z12, directed to MOG augmented clinical disease and demyelination in ABH and C57BL/6 mice, but not MOG knock-out mice. No effect was observed with F(ab(2))' fragments of Z12 or with the anti-MOG IgG1 mAbs, clones Y10 or 8-18C5. Cobra venom factor partially reduced the augmenting effect of mAb Z12 suggesting a role for complement. The pathogenic effect of anti-myelin Abs was not restricted to MOG since an anti-GalC mAb exacerbated inflammation in the CNS while an MBP mAb (clone 22) reduced clinical disease. Taken together, these data provide further evidence that myelin-reactive Abs generated during autoimmune neurological disease may play an important role not only in the pathogenesis of disease but also the regulation of myelin-targeted autoimmune disease.
Morris-Downes
Margaret M
MM
Department of Neuroinflammation, Division of Neurosciences, Imperial College School of Medicine, Charing Cross Campus, London W6 8RF, UK.
Smith
Paul A
PA
Rundle
Jon L
JL
Piddlesden
Sara J
SJ
Baker
David
D
Pham-Dinh
Danielle
D
Heijmans
Nicole
N
Amor
Sandra
S
D000818:Animals; D001323:Autoantibodies / Q000097:blood / Q000276:immunology* / Q000494:pharmacology; D003165:Complement System Proteins / Q000187:drug effects / Q000276:immunology; D003711:Demyelinating Diseases / Q000276:immunology / Q000473:pathology; D004195:Disease Models, Animal; D004546:Elapid Venoms / Q000494:pharmacology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology* / Q000473:pathology*; D005260:Female; D005699:Galactosylceramides / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D004676:Myelin Basic Protein / Q000276:immunology; D009185:Myelin Proteins; D018991:Myelin Proteolipid Protein / Q000276:immunology; D018992:Myelin-Associated Glycoprotein / Q000235:genetics* / Q000276:immunology*; D063308:Myelin-Oligodendrocyte Glycoprotein; D012008:Recurrence; D013116:Spinal Cord / Q000276:immunology / Q000473:pathology
D001323:Autoantibodies; D004546:Elapid Venoms; D005699:Galactosylceramides; C571327:Mog protein, mouse; D004676:Myelin Basic Protein; D009185:Myelin Proteins; D018991:Myelin Proteolipid Protein; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein; C016310:cobra venom factor; C002454:galactocerebroside; D003165:Complement System Proteins